Revenue Recognition and Collaborative Arrangements

9 Months Ended

Sep. 30, 2020

Revenue Recognition and Collaborative Arrangements

Revenue Recognition and Collaborative Arrangements

3. Revenue Recognition and Collaborative Arrangements

Net Revenue from Collaborative Arrangements

Net revenue recognized under our GSK Agreements was as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2020		2019		2020		2019
Royalties from a related party — RELVAR/BREO	$	63,893	$	46,433	$	165,612	$	136,259
Royalties from a related party — ANORO		11,882		11,548		32,931		30,753
Royalties from a related party — TRELEGY		16,375		11,230		48,143		28,401
Total royalties from a related party		92,150		69,211		246,686		195,413
Less: amortization of capitalized fees paid to a related party		(3,456)		(3,456)		(10,368)		(10,368)
Royalty revenue		88,694		65,755		236,318		185,045
Strategic alliance  — MABA program		—		—		10,000		—
Total net revenue from GSK	$	88,694	$	65,755	$	246,318	$	185,045

During the nine months ended September 30, 2020, we recognized $10.0 million in revenue in connection with the termination of the Bifunctional Muscarinic Antagonist-Beta2 Agonist (“MABA”) program under the Strategic Alliance Agreement with GSK in June 2020.